The treatment model for IC is directly formulated based on one or two prevailing theories regarding the disease's etiology. We have developed a comprehensive, systematic, and actionable clinical treatment plan for this challenging condition.
A: Oral Medication Therapy
1.Sodium Pentosan Polysulfate
This is the only FDA-approved medication for IC treatment. Its mechanism corrects the deficiency of glycosaminoglycans in the bladder epithelium. Reports indicate 30-40% of patients experience 40-50% symptom improvement. As it may take 6 months to a year to take effect, long-term oral medication is recommended.
2. Antihistamines
The variable efficacy of antihistamines can be explained by the previously described pathophysiological model: mast cell degranulation represents only one step in the chain of events leading to inflammation and related symptoms. Hydroxyzine should be initiated at 10mg before bedtime, titrated up to 75mg. Symptom relief may take approximately 1-3 months.
3. Antidepressants
The efficacy of antidepressants (TCAs, SSRIs) in treating IC largely stems from their role as pain neuromodulators. Dosages should be gradually increased to minimize side effects. These medications may be initiated early in the disease course, particularly when pain is the predominant symptom.Amitriptyline (Elavil) is typically initiated at 10mg or 20mg before bedtime, titrated up to 75mg if tolerated. Fluoxetine hydrochloride (Prozac) starts at 20mg/day, escalated to 40mg if necessary.Sertraline (Zoloft) is another viable antidepressant with good tolerability. It may be initiated at 50mg/day and titrated up to 100mg/day. Antidepressants exert multifaceted effects: they promote sleep and reduce nocturia; exert neuromodulatory effects by elevating pain thresholds;improve mood; and exert anticholinergic effects on the bladder to reduce frequency caused by detrusor instability. 4. Anticholinergic and Antispasmodic Agents Patients with mild symptoms or concurrent bladder instability may find pain relief with these medications, though they are less effective for moderate to severe symptoms.B: Intravesical Therapy 1. Dimethyl sulfoxide (DMSO) DMSO is an organic solvent with anti-inflammatory, analgesic, and muscle relaxant properties. It also exhibits collagen-dissolving effects. Long-term use may increase the risk of tissue fibrosis and potentially induce specific, progressive resistance after several treatment courses.A retrospective analysis of published data involving over 300 patients revealed that a significant proportion responded well despite its low incidence (32). This drug remains a primary treatment option, with efficacy enhanced when combined with hydrocortisone, heparin, and sodium bicarbonate.The daily dosage involves dissolving 10,000–20,000 units of heparin in 10 mL of saline. Symptom relief lasts 2–6 months, with optimal results after 1–2 years of treatment. Its mechanism resembles sodium pentasulfate polysaccharide, and heparin also restores epithelial permeability.
3. Xishitai
Literature reports indicate that Xishitai bladder instillation effectively repairs the bladder mucosal barrier layer, reducing the invasion of harmful substances into the bladder interstitial layer. This alleviates bladder irritation symptoms such as urinary frequency and dysuria. Effects gradually become apparent after 6-8 instillations. For IC patients, the overall efficacy rate in relieving bladder discomfort is relatively high, approximately 70-80%.For patients with recurrent urinary tract infections (UTIs), long-term bladder irrigation can reduce recurrence rates, particularly in postmenopausal elderly women with recurrent UTIs.
C: Muscle Training
Physical therapy targeting pelvic floor muscles offers therapeutic benefits for IC patients. This approach is grounded in the theory that pelvic floor dysfunction, as an initiating event, can lead to neurogenic inflammation of the bladder wall and increased pelvic floor muscle tension.both of which may contribute to pain. Ten IC patients underwent myofascial physical therapy involving vaginal manipulation: digital compression and lateral traction of periurethral tissues, compression of the pubic urethral muscles toward the symphysis pubis, followed by posterior traction and isovolumetric contraction of the pubovaginalis muscles.
Seven of the ten patients reported moderate to marked (51-99%) symptom relief after an average follow-up of 19 months. Patients with urge-frequency syndrome (considered a milder form of IC) with or without pain also responded to this treatment, with approximately 83% reporting moderate to marked improvement or complete symptom resolution.Transvaginal Theile massage also proved effective for IC patients, with approximately 90% experiencing short-term symptom relief.
Sacral Nerve Modulation (Bladder Pacing)
Sacral nerve stimulation using bladder pacers has recently been employed to treat IC patients with encouraging results.A recent multicenter study found that 60%-80% of patients experienced significant relief from IC symptoms, particularly frequency and pain.
Other authors have reported similar findings, suggesting sacral nerve stimulation may be considered for patients with refractory IC symptoms or poor response to oral or intravesical therapies. The mechanism of action for sacral nerve stimulation remains unclear, but it may be related to IC being a neurogenic bladder condition.Interestingly, the two urinary biomarkers of IC mentioned earlier—heparin-binding epidermal growth factor (HB-EGF) and anti-proliferative factor (APF)—returned to normal levels following IC symptom relief through sacral nerve stimulation. Simultaneously, sacral nerve modulation demonstrated excellent therapeutic efficacy for pelvic pain caused by secondary pelvic floor muscle spasm resulting from refractory interstitial cystitis.
D: Surgical Treatment
1. Cystoscopy and Hydrodistension
As previously noted, cystoscopy and hydrodistension provide therapeutic benefit for some patients, with symptoms improving in 60% of cases within 4–12 months.Although evidence shows elevated urinary HB-EGF levels and reduced APF levels two weeks after hydrodistension-induced muscle stretching, the mechanism remains unclear.
2. Bladder Augmentation, Cystectomy, and Urinary Diversion
Bladder augmentation, cystectomy with urinary diversion remain the final treatment options for patients with persistent symptoms unresponsive to less invasive approaches.The vast majority of patients experience symptom relief following simple cystectomy or supracystectomy with ileal conduit, though a very small number of patients have been reported to persist with refractory pelvic floor pain.